Neumora Therapeutics Inc. Common Stock

NMRA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.69

-$0.04 (-5.48%)

At close: Sep 21, 2026, 4:00 PM ET

$0.72

+$0.03 (+4.32%)

After-hours: Sep 21, 2026, 7:55 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $135.26M

Enterprise Value $11.69M

Beta 2.74

Average Volume 1.7M

Shares Outstanding (Diluted) 185.16M

Shares Change YoY 14.52%

Institutional Ownership 39.13%

Exchange NASDAQ

ISIN US6409791000

Price Performance

Price Change 1M -57.1%

Price Change 3M -57.1%

Price Change 6M -72.4%

Price Change YTD -58.4%

Price Change 1Y -60.1%

Price Change 3Y -93.7%

Price Change 5Y -95.8%

1M CAGR (ann.) -55.5%

1Y CAGR (ann.) -49.7%

5Y CAGR (ann.) N/A

All-Time CAGR -64.3%

Valuation

PE Ratio -0.56

Forward PE N/A

PEG Ratio -0.02

Forward PEG 0.02

PS Ratio N/A

Forward PS 44.20

PB Ratio 2.88

P/FCF Ratio -0.71

P/Adj. FCF Ratio -0.61

P/OCF Ratio -0.71

EV/Sales N/A

EV/EBIT -0.06

EV/EBITDA -0.06

EV/FCF -0.06

Earnings Yield -178.3%

FCF Yield -140.8%

Adj. FCF Yield -162.7%

Financial Health

Net Cash $116.49M

Total Debt $340K

Cash & Short-Term Investments $116.83M

Total Assets $125.25M

Current Ratio 4.50

Quick Ratio 4.50

Debt / Equity Ratio 0.01

Debt / EBITDA -0.00

Debt / FCF -0.00

OCF / Debt -530.94

Interest Coverage -32.71

Altman Z-Score -17.84

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -15.5%

Returns

Return on Assets -169.9%

Return on Equity -242.3%

Return on Invested Capital -216.1%

Return on Capital Employed -216.7%

Return on Tangible Assets -169.9%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 16.6%

EPS CAGR 5Y 3.4%

EPS CAGR 10Y N/A

FCF CAGR 3Y 4.7%

FCF CAGR 5Y -14.0%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 9

EPS Growth Next 3Y 16.3%

Revenue Growth Next 3Y N/A

Earnings Date N/A

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $4.50

Price Target Upside 552.2%

Cash Flow

Operating Cash Flow $-180.52M

Free Cash Flow $-180.52M

Adj. Free Cash Flow $-208.5M

FCF Per Share -$0.97

OCF Per Share -$0.97

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-5.01M

Operating Income $-211.23M

EBITDA $-207.14M

Net Income $-212.75M

EPS (Diluted) -$1.23

Revenue / Employee N/A

Profit / Employee $-3.38M

Employees 63